OESO-SEMPIRE 17th World Conference | Esophagus 2026 | Versailles | June 14-17, 2026

Session 33: Challenging cases in Oncology

Wednesday, June 17, 2:00 – 3:30 pm
Auditorium Condé

Chairs: Manfred Lutz (Germany) – Christelle De la Fouchardière (France) – Dave H. Wang (USA)

  1. HER2-Targeted Therapies: new upcoming trials in gastroesophageal cancers. – Alberto Puccini (Italy)
  2. Role of Immunotherapy for long-term survivorship. – Markus Moehler (Germany) 
  3. Claudin 18.2 Therapies for Gastroesophageal Cancer: full remission possible? – Jean-Philippe Metges (France)
  4. Thinking out of the box with localized disease or TNT. – Ines Gockel (Switzerland)
  5. CtDNA guidance? PLAGAST and more. – Catherine Streutker (Canada)
  6. When de-escalation after first line? – Sara Lonardi (Italy)
  7. Liver limited disease: resect metastases like in colon cancer? – Beat Müller (Switzerland) 
  8. Oral Abstract Presentation: Comparative Outcomes of Neoadjuvant Immunochemotherapy Versus Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Cancer: A Real-World Study. – Zhiyu Li (China)
  9. Oral Abastract Presentation: Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study. – Yuquan Bai (China) 

 

Session Format:
Presentations: Nine topics will be addressed with prepared presentations.
Each speaker will be given 10 minutes to discuss the assigned topic.